An essential requirement to understand how genes contribute to genetic disease is the thorough knowledge of the transcriptional regulation of gene expression. Here, we have characterized transcription factor binding sites within the type 1 neurofibromatosis (NF1) proximal regulatory region, and addressed the molecular mechanisms that regulate NF1 transcription. Overlapping regions of the NF1 proximal promoter have been cloned and characterized for use in luciferase reporter assays. These assays have identified a 500 bp region displaying activities up to 80-fold higher than control reporter levels. Mutations at putative CRE and SP1-binding sites immediately 5 0 to the transcription start site have dramatic effects that lead to a 70-90% decrease in reporter activity in all cell lines tested. Gelshift assays confirm binding of CREB and SP1/KLF family members to their putative recognition sequences, and provide the first evidence identifying functional sites likely involved in regulating NF1 transcription. These assays have also revealed a putative repressor region within the NF1 promoter region corresponding to CCCTC-rich sequences between the transcription and translation start sites. This work provides new information concerning the transcriptional regulation of the NF1 gene, and is the most thorough attempt to date to map functionally relevant regions within the NF1 proximal promoter region.
Introduction
Type 1 neurofibromatosis (NF1) is a multisystem genetic disorder that predisposes affected individuals to a variety of cutaneous, orthopedic and neurologic manifestations (Rubenstein and Korf 1990) . The defined diagnostic criteria for NF1 include multiple cafe´-au-lait macules and regional freckling of the skin, hamartomas (Lisch nodules) of the iris, multiple cutaneous and/or internal plexiform neurofibromas, optic glioma, as well as bone lesions that can include thinning of the long bones with pseudarthritis (NIH Consensus Statement, 1988; Stumpf et al., 1988) . More than half of the children with NF1 have learning disabilities and their mean scores on tests of intellectual function are lower than expected (Hofman et al., 1994) . The clinical consequences for affected individuals are variable, given the fact that neurofibromas can affect any organ of the body and that the disease increases in severity with age. The life expectancy of patients with NF1 is reduced by at least 15 years overall (Zoller et al., 1995) , due in part to an increased risk for hypertension and to the development of NF1-associated malignancies. These malignancies include leukemia and lymphoma that develop more frequently than expected in children with NF1 (Stiller et al., 1994) , as well as malignant peripheral nerve sheath tumours (MPNSTs) that may have a lifetime risk in NF1 patients as high as 8% (Evans et al., 2002) .
Recent work directed at the molecular biology of the NF1 gene has resulted in the development of useful mouse and Drosophila model systems that are being used to clarify the role of the NF1 gene as an important regulator of Ras function (Guha, 1998; Reed and Gutmann, 2001) . The large, complex NF1 gene encodes the protein neurofibromin that appears to have a primary function as a GTPase activating protein (GAP; Cichowski and Jacks, 2001) . A functional GAP domain encoded within neurofibromin attenuates Ras function by rapidly converting active GTP-Ras to the inactive GDP form (Adjei, 2001) . As a result, a number of laboratories have undertaken studies to address the specific involvement of neurofibromin in the posttranslational regulation of Ras and downstream MAP kinase and adenylyl cyclase pathways (Kim et al., 2001; Tong et al., 2002) . In contrast, a basic understanding of the transcriptional regulation of the NF1 gene is limited. Hajra et al. (1994) cloned and sequenced the promoter regions of the human and mouse NF1 genes and mapped the transcriptional start sites in both species. This group reported that the 5 0 ends of the human and mouse NF1 genes were highly conserved and that several putative, conserved transcription factor binding site motifs were contained within a region between nucleotides (nts) À33 and þ 261. These sites also provide possible targets for aberrant DNA methylation, which can alter gene expression by interfering with the initiation of transcription (Clark and Melki, 2002; Jones, 2002) or through changes in chromatin structure (Robertson, 2002) . Our laboratory has established a methylation map of the promoter region of the NF1 gene and demonstrated functional sensitivity for methylation at specific sites for the SP1-and CRE-binding (CREB) proteins in the NF1 regulatory region (Mancini et al., 1999) .
In the present report, we extend our earlier studies by further characterizing the NF1 proximal regulatory region. Overlapping regions of the NF1 proximal promoter have been cloned and luciferase reporter assays have identified a region within which lie the binding sites for CREB and SP1/ KLF family members that can be inactivated by site-directed mutagenesis. Furthermore, we have identified a putative repressor region within the NF1 promoter region that includes CCCTC-rich sequences located between the transcription and translation start sites. This work begins to provide a clearer understanding of the functional sites within the NF1 regulatory region that are responsible for regulation of NF1 gene expression.
Results

Cloning of NF1 promoter sequence and reporter construction
Luciferase reporter constructs were generated by inserting overlapping subregions of the NF1 promoter into the pGL3-basic vector (Figure 1 ). Background luciferase activities (relative light units/mg protein: RLU/mg protein) were determined for the pGL3-basic vector and with pGL3-SV40 as a positive control. Luciferase activities for all constructs are shown as RLU/mg protein ( Figure 3 and Table 2 ), or as a fold increase in reporter activity relative to pGL3-basic experiments (i.e. # times pGL3; Figures 4 and 5) .
We used reverse transcriptase-PCR (RT-PCR) to show that neurofibromin mRNA was expressed in each of the cell lines used in our transfection experiments (Figure 2a) , and Western blots to confirm expression of neurofibromin by these cells (Figure 2b ). Interestingly, while neurofibromin was detected in three of the cell lines ( Figure 2b ; lanes 1-3 and 5-7), the Western blots failed to detect the full-size neurofibromin in HTB186 cell extracts but did identify an aberrant protein product smaller than the expected 250 kDa protein (lanes 4,8) . This suggests that these cells likely have low levels of functional neurofibromin.
We found that in each of the cell lines, we were able to maximally drive expression of the luciferase reporter with a 425 bp fragment (pMXNF-13) containing intact Characterizing the NF1 promoter M-X Zou et al sequences flanking the putative NF1 transcription start site (Figure 3 ). pMXNF-13 dramatically displayed reporter activities that were from 45 to 180 times higher than those seen with the pGL3-basic reporter, depending on the transfected cell type. The activities seen with pMXNF-13 were similar to pMXNF-23 and were consistently 2-3-fold higher than pMXNF-53, and 5-10-fold higher than pMXNF-14. These other constructs showed variable but significant activities that were apparently dependent on the presence of specific DNA sequences. For example, pMXNF-23, which lacked a previously described SP1-binding site (at nt position À141), had the next highest activities, which ranged from 34-177-fold higher than pGL3. The reporter pMXNF-53, which contained a further 1100 bp of 5 0 sequence, displayed more decreased levels of activity, ranging from 10-68-fold, while comparative low values were also observed following the transfection of pMXNF-14 (only seven to eight times above the baseline pGL3 activity). We did detect some variation among the various cell lines with respect to apparent promoter strength of these constructs. The lowest luciferase values were seen with the HeLa and HTB186 cells. Interestingly, HTB186 was also the cell line shown to be deficient for the expression of neurofibromin by Western blotting (Figure 2b ) and both HeLa and HTB186 displayed 3-4-fold lower levels of transfection efficiency, relative to HTB 11 and 293 cells. Despite these differences, our reporter data were consistent within each of the particular cell lines for each of the transfected constructs and in all experiments performed.
Subsequently, the increases in reporter activities seen with pMXNF-13 (relative to pMXNF-14 and -53) prompted us to explore the regulatory motifs within pMXNF-13 by creating site-directed mutations at CpGs within the CRE and SP1 factor binding sites (Figure 4) . Direct comparison between pMXNF-13 and reporters pMXNF-13S and -13C show up to a 90% decrease in activity when the CRE (64-90% decrease) or the SP1 sites (70-87% decrease) are mutated. These transient transfection experiments are supportive of a functional role for these particular transcription factors in regulating NF1 gene expression.
The low reporter activities seen with pMXNF-14 prompted us to further evaluate the region of the NF1 promoter within the 5 0 -UTR. Therefore, we generated several reporter constructs that differed on the basis of 3 0 sequences present between þ 155 and þ 539. As seen in Figure 5 , three further NF1 reporter constructs (pMXNF14.1, 14.2 and 14.3) were generated. Interest- Figure 3 Luciferase expression assays. Luciferase activities (RLU/ mg protein) were determined for a series of vectors that spanned the NF1 promoter region as indicated in Figure 1 . Background luciferase activities were also determined for the pGL3-basic vector. At least three sets of transfections (each in triplicate) were performed for each of the cell lines ingly, transfections with these reporters revealed that deletion of sequences between þ 230 and þ 534 present in pMXNF-14.2 and pMXNF-14.3 led to pMXNF-14.1 having a dramatically higher reporter activity than those seen with the full-length pMXNF14. In fact, pMXNF-14.1 displayed promoter activities that were restored to levels that were even greater than pMXNF-13. These results further define a 500 bp minimum proximal promoter region of the NF1 gene (À270 to þ 230) and suggest that a repressor region exists within the 300 bases immediately upstream of the NF1 translation start site ( þ 231 to þ 539).
Gelshift assays
Electrophoretic mobility shift assays (EMSAs) were performed to characterize the functional specificity of the CRE and SP1 motifs identified within the NF1 promoter. These gelshift experiments involve oligonucleotides targeted to the CRE and Sp1 motifs as well as oligonucleotides in which we have introduced point mutations at CpGs contained with these motifs. Nuclear extracts were prepared from cultured cells and incubated with annealed oligonucleotides containing the normal/ mutant CRE or Sp1-binding sites.
Representative gelshift results for the NF1 CRE ( Figure 6 ) showed that a distinct set of proteins is bound to the oligonucleotide corresponding to the Figure 4 Luciferase expression assays with mutagenized constructs. Constructs were generated from the pMXNF13 construct and contained site-directed mutations at CpGs within the CRE (pMXNF13C) and SP1 (pMXNF13S) factor binding sites. Luciferase activities from this experiment are presented as the fold increase in reporter activity relative to the background activities determined for the pGL3-basic vector. As well, percentage values (%) indicate the expression levels of the mutated constructs (13C and 13S) relative to the parent pMXNF13 vector. At least three sets of transfections (each in triplicate) were performed for each of the cell lines Figure 5 Evidence of a repressor region within pMXNF14. Reporter constructs were generated from pMXNF14 that differed on the basis of 3 0 sequences present between þ 155 and þ 539 (pMXNF14.1, 14.2 and 14.3; as indicated in Figure 1 ). Luciferase activities from this experiment are presented as the fold increase in reporter activity relative to background activities determined for the pGL3-basic vector. At least three sets of transfections (each in triplicate) were performed for each of the cell lines Figure 6 Gel mobility shift and competition assays at the CRE. Lanes 1 and 9 show free template, and all other lanes utilized nuclear extract from HeLa cells (NE). A variety of conditions were used (i.e. supershifts or competition with unlabelled oligonucleotides) and are indicated with ( þ ) at the top of the figure. Competitions with excess unlabelled oligonucleotides ('cold') were performed in lane 3 (nonspecific NF1 oligonucleotide: NF01), lanes 4,5 (oligo with mutated CRE sequence: mCRE) and lanes 7, 8, 10, 12 (normal oligonucleotides). Supershift assays with anti-CREB (aCRE) were performed in lanes 5, 6, 11 normal CRE sequence located 8 bp upstream of the transcription start site ( Figure 6 , lane 2). Competition with the unlabelled CRE oligonucleotide dramatically decreased binding of most proteins in the complex (lanes 7,8) . In contrast, competition with a nonspecific oligonucleotide (lane 3) had no effect on binding. In other experiments, protein binding was dramatically decreased when we used oligonucleotides containing a single CG to TG mutation (lanes 10-12), and some inhibition of protein binding was seen with competition with an oligonucleotide containing this CG to TG mutation (lanes 4 and 5). These results confirm previous experiments that show that an intact CRE is required for optimal binding of a protein complex that includes the CREB protein.
Gelshifts were also performed to address the functionality of several previously described but putative SP1 sites in the NF1 promoter region (Hajra et al., 1994 ). First, we tested the SP1 site at -141 and found that a distinct set of proteins bound to the oligonucleotide corresponding to the normal SP1 sequence ( Figure 7 ; lane 2). We identified one band that reacted with the anti-SP1 antibody (lane 5). In contrast, competition assays with excess unlabelled oligonucleotides (lanes 3 and 4) dramatically inhibited binding of this protein. As well, mutating the SP1 recognition sequence (lanes 7-9) also eliminated SP1 binding. This site is within the 167 bp region that is deleted in pMXNF23 in comparison to pMXNF13 luciferase reporter construct. Deletion of this region from pMXNF23 resulted up to an 11-fold decrease in reporter activity (Figure 3 ), suggesting that this SP1 site may be partially responsible for optimal NF1 expression.
Further experiments focused on putative SP1-binding sites at þ 415 and þ 460 (Figure 8) . Gelshifts revealed the binding of protein complexes (lanes 2 and 7) and supershifts detected SP1 binding at each of these sites (lanes 3 and 8). In several experiments we also investigated whether other SP1 family members were also members of these complexes. In particular, we addressed Kruppel-like factors (KLF), which are DNAbinding zinc-finger proteins of the SP1 multigene family, that regulate transcription and have diverse roles in both differentiation and development (Crossley et al., 1996; Bieker, 2001) . Gelshifts were performed, as were supershift assays using antibodies recognizing the carboxy (M-19) or amino termini (T16) of gut-enriched KLF (GKLF). We did observe a supershift with the M19 antibody at the þ 460 SP1 site (lane 14). This binding could be inhibited by preincubating the antibody with blocking peptide. The M19 antibody recognizes the carboxy end of GKLF as well as other members of the KLF family. Since the GKLF-specific T16 antibody did not detect a protein within this complex (lane 15), our data suggest that another member of the KLF family may be involved in this protein complex.
Methylation effects on NF1-luciferase constructs
Aberrant DNA methylation has been shown to occur frequently in tumors within the promoter regions of a wide variety of tumor suppressor genes. No extensive studies have evaluated the frequency or location of NF1 promoter region methylation in NF1-associated tumors. To establish in vitro a proof-in-principle that aberrant methylation within the proximal promoter could contribute to NF1 tumorigenesis, we synthesized and transfected in vitro methylated luciferase reporter constructs. To minimize the nonspecific effects of methylation, 'patch-methylated' constructs were synthesized in which we ligated methylated NF1 promoter fragments into unmethylated pGL3 vectors. In these experiments that were performed in triplicate, we determined that methylation had a profound effect on expression of the reporters (Table 2) , reducing levels to as low as 1% of their respective mock-methylated controls. These results show that a change in the methylation status within the NF1 promoter can alter reporter activity and are suggestive that aberrant methylation at these sites in vivo may play a complementary role to mutagenesis 
Discussion
In the present paper, we have extended our earlier studies by further characterizing functional sites responsible for the regulation of NF1 gene expression (Mancini et al., 1998) . To this end, luciferase reporter constructs were generated by inserting overlapping NF1 subregions into the pGL3-Basic vector (Figure 1 ). We were able to maximally drive expression of the luciferase reporter with a 425 bp fragment (pMXNF-13) containing intact sequences flanking the putative NF1 transcription start site (Figure 3 ). pMXNF-13 displayed reporter activities that were up to 180 times higher than those seen with the pGL3-basic reporter, while other constructs showed variable activities. For example, pMXNF-23 that lacks 167 bp containing a SP1-binding site (at nt position -141) had the next highest activities, and these were slightly less than pMXNF-13. By site-directing a mutation at the SP1 site within pMXNF-13 (Figure 4 ), we were able to dramatically decrease reporter activity, suggesting that this SP1 site has an important role in regulating NF1 transcription.
In other experiments, pMXNF-14 reporter activities were significantly (2-3-fold) lower than pMXNF-13. To better define this region, we generated several reporter constructs (pMXNF14.1, 14.2 and 14.3) that differed on the basis of 3 0 sequences present between þ 155 and þ 539. The lower reporter activities appeared to be due to the inclusion of sequences between þ 230 and þ 434 in pMXNF-14.2 and pMXNF-14.3 ( Figure 5 ). In contrast, pMXNF-14.1 displayed high reporter activities that were restored to levels that were even greater than pMXNF-13. These results define the minimum proximal promoter region of the NF1 gene (À270 to þ 230) and further suggest that a repressor region exists within the 300 bases upstream of the NF1 translation start site ( þ 354 to þ 539). Multiple putative AP2-binding sites previously described by Hajra et al. (1994) are likely candidates as repressor sequences in this region, with at least four potential AP2 sites between þ 230 and þ 434. Previous reports have shown that AP2 can repress the human acetylcholinesterase gene (ACHE) and mouse Ache transcription in transfection and in vitro transcription experiments (Getman et al., 1995) . Furthermore, AP2-mediated repression may be part of the molecular mechanism responsible for regulating hepatocyte growth factor (HGF) expression (Jiang et al., 2000) . Our data suggest that NF1 may be another gene at which AP2 binding may have a repressor effect and that AP2 may be subject to complex patterns of regulation. Two of the cell lines used in the transfection experiments showed lower reporter activities that were consistent and proportional for each of the transfected constructs. These low luciferase values observed with the HeLa and HTB186 cells are likely associated with the lower transfection efficiencies seen with these two cell lines as determined by cotransfection with a lacZ expression vector. As well, Western blots (Figure 2b ) Gelshift assays further demonstrated the functional specificity of the CRE and SP1 motifs previously identified within the NF1 promoter (Mancini et al., 1999) . Significant decreases in activity were seen when pMXNF-13S (70-87% decrease) and pMXNF-13C (64-90% decrease) were mutated (Figure 4) . Gelshifts showed that a distinct set of proteins is bound to the oligonucleotide corresponding to the normal CRE sequence located 8 bp upstream of the transcription start site (Figure 6 , lane 2), and protein binding was dramatically decreased when we used oligonucleotides containing a single CG to TG mutation (lanes 10-12) . These results confirm previous experiments that show that an intact CRE is required for optimal binding of a protein complex that includes the CREB protein (Mancini et al., 1999) .
SP1 is the prototype for a large multigene family of highly homologous transcription factors with diverse roles in cell growth and tumor progression (see reviews by Suske, 1999; Black et al., 2001) . SP1 sites are found in the promoters of many housekeeping genes, supporting a role for SP1 as a basal transcription factor (Dynan and Tjian, 1985; Black et al., 2001) . We tested the SP1 site at À141 and found that a distinct set of proteins bound to the oligonucleotide corresponding to the normal SP1 sequence (Figure 7 ; lane 2). One fraction within this complex reacted with the anti-SP1 antibody (lane 5), while competition assays with excess unlabelled oligonucleotides (lanes 3 and 4) dramatically inhibited binding of this protein complex to the labelled oligonucleotide. As well, mutating the SP1 recognition sequence (lanes 7-9) also eliminated SP1 binding. Further experiments revealed that at least two other SP1 sites are located in the NF1 promoter region at þ 415 and þ 460 (Figure 8) . Gelshifts revealed the binding of protein complexes (lanes 2 and 7), and supershifts detected SP1 binding at each of these sites (lanes 3 and 8) .
We also investigated whether KLF of the SP1 family members also bound to these NF1 oligonucleotides. KLF are DNA-binding zinc-finger proteins that regulate transcription and have diverse roles in both differentiation and development, including as transcriptional repressors (Crossley et al., 1996; Bieker, 2001) . Gelshifts were performed (Figure 8 ), as were supershift assays using antibodies recognizing the carboxy (M-19) or amino termini (T16) of GKLF. We did observe a supershift with the M19 antibody at the þ 460 SP1 site (lane 14). This binding could be inhibited by preincubating the antibody with blocking peptide. The M19 antibody recognizes the carboxy end of GKLF as well as other members of the KLF family. Since the GKLFspecific T16 antibody did not detect a protein within this complex (lane 15), our data suggest that another member of the KLF protein family may be involved. Together, these results support a role for SP1 and related KLF family members as important regulators of NF1 transcription.
Finally, we addressed a potential role for DNA methylation in the regulation of NF1 gene expression. Therefore, in the present paper we transfected methylated luciferase reporter constructs to establish in vitro a proof-in-principle that aberrant methylation within the proximal promoter could contribute to NF1 tumorigenesis. Our results showed that methylation had a profound effect on expression of the reporters (Table 2) , reducing levels to as low as 1% of their respective mock-methylated controls. These results show that a change in the methylation status within the NF1 promoter can alter reporter activity and are suggestive that aberrant methylation at these sites in vivo may play a complementary role to mutagenesis in the epigenetic inactivation of this gene in NF1-related tumors.
The role of NF1 as a tumor suppressor gene is consistent with the concept that this gene would be a candidate for epigenetic inactivation through promoter hypermethylation. Current models suggest that DNA methylation inhibits transcription by interfering with the initiation of transcription (Clark and Melki, 2002; Jones, 2002) or through changes in chromatin structure, and histone acetylation levels mediated by histone deacetylases (Robertson, 2002) . Aberrant DNA methylation has been shown to occur frequently in tumours within the promoter regions of a wide variety of other tumor suppressor genes, where methylation provides one of the hits postulated by Knudson's two-hit hypothesis to inactivate tumor suppressor genes (Plass and Soloway, 2002) . For example, Kino et al. (2001) have reported that suppressed expression by methylation could be an alternative mechanism for inactivation of the NF2 gene.
In contrast, only two studies have addressed DNA methylation in the context of the NF1 gene (Horan et al., 2000; Luijten et al., 2000) . In particular, Horan et al. (2000) tested a limited number of NF1-related neurofibromas and peripheral blood cells, and observed tumorspecific cytosine methylation at only a small number of cytosines upstream of the transcription start site. The variable methylation that this group observed may reflect tissue heterogeneity and/or differences in the developmental staging of particular neurofibromas. Also, as these authors discussed, a much larger number of tumor samples would need to be screened to exclude the involvement of DNA methylation as an epigenetic event in NF1 tumorigenesis, since methylation is one of a number of mechanisms contributing to tumorigenesis (Plass and Soloway, 2002) . These possibilities, therefore, do not rule out promoter hypermethylation as a contributor of NF1 inactivation in a restricted subset of NF1-related tumors. Our present data, along with our previous data (Mancini et al., 1999) support the principle that aberrant methylation could act as a downregulator of NF1 expression and that these epigenetic effects are focused on specific subregions within the Nf1 promoter that are in close association with the specific SP1 and CRE sites in the NF1 regulatory region (Mancini et al., 1999) . Together, the data in this present paper confirm the presence of functional sites within the NF1 regulatory region. Further work will be needed to understand how both genetic and epigenetic factors can regulate NF1 expression, and how these pathways can be targeted to perhaps modulate NF1 expression at the level of transcription.
Materials and methods
Cell culture
HeLa cells, human embryonic kidney 293 cells, HTB11 and HTB186 neuroblastoma cells (ATCC) were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with L-glutamine (200 mM), HEPES (10 mM), penicillin (100 mg/ml), streptomycin (100 mg/ml) and 10% fetal bovine serum (FBS). These cells were maintained in a humidified incubator at 371C with 5% CO 2 .
mRNA and protein expression
Cells were grown in monolayer in DMEM plus 10% FBS and RNA was isolated using TRlzol following the manufacturers' protocol (Gibco-BRL). To confirm expression of the NF1 mRNA, mRNA was isolated from each of the four cell lines and RT-PCR was performed (Ready-To-Go RT-PCR kit; Amersham Pharmacia Biotech) using primers specific for sequences in NF1 exons 29 and 31 (5 0 -ggagtgtgaagccattgtccag-3 0 and 5 0 -ggcatcatcattatgcttgc-3 0 ). The RT-PCR reaction occurred under the following conditions: 421C for 25 min, then 5 min at 951C followed by PCR for 32 cycles: 5 min at 951C. PCR was undertaken as follows: 951C (1 min), 551C (1 min), 721C (1 min).
For Western blotting, whole-cell lysates were collected from 293 cells using RIPA buffer (1XPBS, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS) to which the following inhibitors were added: 10 mg/ml PMSF (10 ml/ml RIPA), aprotinin (30 ml/ml RIPA; Sigma A6279) and 100 mM sodium orthovanadate (10 ml/ml RIPA) after washing with PBS. The lysate was passed through a 21-gauge needle and placed on ice for 60 min followed by centrifugation at 10 000 g (10 min/41C). Whole-cell lysates (50 mg) were electrophoresed on polyacrylamide gels (5% stacking gel/6% separating SDS gel) followed by transfer to nitrocellulose membrane (Amersham Pharmacia Biotech) using the Mini Trans-Blot electrophoretic transfer cell (BioRad) following the standard protocol for 80 min at 100 V. Membranes were washed and antibody incubation was carried out following the protocol for ECL Plus (Amersham Pharmacia Biotech). The primary antibodies were rabbit polyclonal antibodies against N-and C-terminal epitopes of the neurofibromin protein (Santa Cruz antibodies SC-67 and SC-68; dilutions of 1 : 2500). The secondary antibody was a horseradish peroxidase (HRP)-conjugated antibody (mouseanti-rabbit IgG; SC-2357; Santa Cruz; dilution of 1 : 1250). Membranes were incubated with ECL Plus and the chemiluminescence was detected using Kodak X-Omat AR film.
Plasmid construction
DNA fragments containing NF1 sequences for the reporter constructs were generated by PCR using primers specific to human NF1 sequences reported by Hajra et al. (1994) and from Genbank (HSU17084). These sequences were confirmed using working draft sequence from the Human Genome Database (AC027793). This 148 kb unordered contig sequence contains a 16 kb fragment possessing the NF1 5 0 UTR and the transcription start site. Five separate PCR primers (Table 1; primers DRNF1-5) were designed and used to amplify separate regions in the CpG-rich NF1 promoter region corresponding to sequences encompassing primers 2-3 (259 bp), 1-3 (426 bp), 2-4 (693 bp), 1-4 (810 bp) and 5-3 (1522 bp; Figure 1 ). The resulting PCR products were ligated into the TOPO-TA cloning vector (Invitrogen), transformed into bacteria and then screened. Clones positive for the NF1 insert were sequenced at our core DNA sequencing facility to ensure sequence fidelity prior to direct cloning into the PGL3 luciferase reporters. In several cases, PCR primers were designed with XhoI and HindIII restriction sites included at their 5 0 ends to allow for cloning into the PGL3 luciferase expression vectors.
In several experiments, we performed site-directed mutagenesis at putative transcription factor binding sites to create site-mutagenized reporter constructs (described previously; Marcini-Dinardo et al., 2001) . Specifically, the CRE in pMXNF13 was changed at the central CpG dinucleotide to a TpG dinucleotide (TGACGTCA-TGATGTCA) to create pMXNF13c (with primer DRNF365). As well, the Sp1 site in pMXNF13 was also altered (GGGGCGG-GGGGTAA) to create pMXNF13s (with primer DRNF369). These reporter constructs were sequenced to verify the presence of the mutation. In other experiments, deletion constructs 14.1, 14.2 and 14.3 were generated using an appropriate set of PCR primers internal to pMXNF14. 
Mammalian cell transfection
Transfections were carried out as previously described (Mancini-Dinardo et al., 2001) . Briefly, 10 5 cells were seeded in each well of six-well 35 mm 2 tissue culture plates. Transfections were carried out in triplicate (three separate transfections for each experimental condition, performed on the same day) using 4 ml of lipofectamine reagent (Invitrogen) and 1 mg of either the methylated or mock-methylated plasmids. In all experiments, at least three sets of transfections (each in triplicate) were performed for each of the cell lines. Cells were harvested 48 h after transfection and the cell lysates were assayed for luciferase activity using the protocols from the Promega luciferase kit. Total protein was determined by Bradford assays; luciferase activities were determined ( Figure 3 and Table 2) , and/or presented as a fold increase relative to pGL3-basic (Figures 4 and 5) . We confirmed equivalent transfection efficiencies for the pGL3 vectors by cotransfecting with the pSV-b galactosidase vector and determining bgalactosidase expression in the cell lysates (data not shown).
Gelshift assays
Gel mobility shift assays were designed to confirm specific binding of the CREB and SP1 proteins in this region of the NF1 promoter using methods previously described (Mancini et al., 1999; Marcini-Dinardo et al., 2001) . Briefly, oligonucleotides were used that contained the putative CRE (DRNF363, DRNF364) or SP1 (DRNF367, DRNF368) elements. Nuclear extracts were prepared from HeLa cells as previously described (Mancini-Dinardo et al., 2001 ) and these extracts were stored at À801C until use. In all experiments, double-stranded oligonucleotides were end labelled with [g-32 P]ATP (Amersham; 6000 Ci/mmol, 1 Ci ¼ 37 GBq) using T4 polynucleotide kinase, with electrophoresis and autoradiography performed as previously described (Mancini et al., 1998) .
Plasmid methylation
To address the effect of methylation on reporter constructs, inserts were digested from the reporters and methylated using 8 U of SssI methylase (NEB) at 371C for 8-13 h. After a subsequent inactivation of enzyme at 601C for 20 min, the 'patch-methylated' inserts were religated into unmethylated pGL3 vectors prior to transfection. Mock-methylation reactions were also performed in the absence of SssI methylase and S-adenosyl methionine. The methylated and mock-methylated constructs were purified using PCR purification columns (Invitrogen) and the methylation status of each construct was determined by HpaII digestion.
